Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Herpesvirus entry mediator (HVEM; TNFRSF14; CD270) is a type I transmembrane protein belonging to the tumor necrosis factor receptor superfamily. It serves as a crucial immune regulatory receptor, binding ligands such as LIGHT (TNFSF14), lymphotoxin-beta, and viral envelope proteins (herpesvirus glycoprotein D). HVEM mediates signal transduction that promotes T and B cell activation, enhances cytokine production, and regulates apoptosis and immune defense in both normal and disease contexts. HVEM’s interactions establish a critical checkpoint for lymphocyte proliferation, tissue architecture, and host defense, and dysregulation of this pathway has been implicated in a range of inflammatory, infectious, and malignant conditions. Targeting HVEM or its ligands is being pursued for disease intervention, but care must be exercised due to its wide-ranging roles in immune function
Antagonism of LIGHT binding (e.g., neutralizing antibodies to block LIGHT-HVEM interaction); Modulation of NF-κB signaling downstream of receptor activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpesvirus entry mediator receptor (HVEM).